Prediabetes: The Importance of Early Identification and Intervention

References

• . Garber AJ, Handelsman Y, Einhorn D,. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933–946
   PubMedGoogle Scholar
• . McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J. 1999;138(5 pt 1):S366–S375
   Web of Science ®Google Scholar
• . Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006;2(5):269–281
   PubMedGoogle Scholar
• . Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783–788
   PubMed Web of Science ®Google Scholar
• . Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33( suppl 1):S62–S69
   PubMedGoogle Scholar
• . Centers for Disease Control and Prevention. Number of people with diabetes increases to 24 million. 2008. http://www.cdc.gov/media/pressrel/2008/r080624.htm. Accessed March 26, 2010
   Google Scholar
• . International Diabetes Federation. Diabetes atlas. Diabetes and impaired glucose tolerance. Global burden: prevalence and projections, 2010 and 2030. http://www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance. Accessed October 27, 2009
   Google Scholar
• . Centers for Disease Control and Prevention. Self-reported pre-diabetes and risk-reduction activities—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(44):1203–1205
   PubMedGoogle Scholar
• . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
   PubMed Web of Science ®Google Scholar
• . Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8–13
   PubMed Web of Science ®Google Scholar
• . Viswanathan V, Clementina M, Nair BM, Satyavani K. Risk of future diabetes is as high with abnormal intermediate post-glucose response as with impaired glucose tolerance. J Assoc Physicians India. 2007;55:833–837
   PubMedGoogle Scholar
• . Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101(9):975–980
   PubMed Web of Science ®Google Scholar
• . Knowler WC, Barrett-Connor E, Fowler SE,. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403
   PubMed Web of Science ®Google Scholar
• . Tirosh A, Shai I, Tekes-Manova D,; Israeli Diabetes Research Group. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353(14):1454–1462
   PubMed Web of Science ®Google Scholar
• . Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I. Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev. 2007;23(7):551–558
   PubMed Web of Science ®Google Scholar
• . Barr EL, Zimmet PZ, Welborn TA,. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116(2):151–157
   PubMed Web of Science ®Google Scholar
• . Levitzky YS, Pencina MJ, D'Agostino RB,. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol. 2008;51(3):264–270
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–494
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Yusuf S, Bosch J,; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–1105
   PubMed Web of Science ®Google Scholar
• . Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129–1134
   PubMed Web of Science ®Google Scholar
• . DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26(3):688–696
   PubMed Web of Science ®Google Scholar
• . Vinik AI, Strotmeyer ES, Nakave AA, Patel CV. Diabetic neuropathy in older adults. Clin Geriatr Med. 2008;24(3):407–435
   PubMed Web of Science ®Google Scholar
• . Singleton JR, Smith AG. Neuropathy associated with prediabetes: what is new in 2007? Curr Diab Rep. 2007;7(6):420–424
   PubMedGoogle Scholar
• . Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist. 2008;14(1):23–29
   PubMed Web of Science ®Google Scholar
• . Sahin M, Karatas M, Sahin M,. High prevalence of neuropathy in patients with impaired 60-minute oral glucose tolerance test but normal fasting and 120-minute glucose levels. Minerva Endocrinol. 2008;33(4):289–296
   PubMed Web of Science ®Google Scholar
• . Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164(9):1021–1025
   PubMedGoogle Scholar
• . Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10(2):393–400
   PubMed Web of Science ®Google Scholar
• . Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24(2):137–144
   PubMed Web of Science ®Google Scholar
• . Wong TY, Liew G, Tapp RJ,. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(9614):736–743
   PubMed Web of Science ®Google Scholar
• . Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233–240
   PubMed Web of Science ®Google Scholar
• . Yanko L, Goldbourt U, Michaelson IC, Shapiro A, Yaari S. Prevalence and 15-year incidence of retinopathy and associated characteristics in middle-aged and elderly diabetic men. Br J Ophthalmol. 1983;67(11):759–765
   PubMed Web of Science ®Google Scholar
• . Nang EE, Khoo CM, Tai ES,. Is there a clear threshold for fasting plasma glucose that differentiates between those with and without neuropathy and chronic kidney disease?: the Singapore Prospective Study Program. Am J Epidemiol. 2009;169(12):1454–1462
   PubMed Web of Science ®Google Scholar
• . Haffner SM, Gonzales C, Valdez RA,. Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia. 1993;36(10):1002–1006
   PubMed Web of Science ®Google Scholar
• . Mykkänen L, Haffner SM, Kuusisto J, Pyorälä K, Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes. 1994;43(4):552–557
   PubMed Web of Science ®Google Scholar
• . Tapp RJ, Zimmet PZ, Harper CA,; AusDiab Study Group. Diagnostic thresholds for diabetes: the association of retinopathy and albumin-uria with glycaemia. Diabetes Res Clin Pract. 2006;73(3):315–321
   PubMed Web of Science ®Google Scholar
• . Franciosi M, Pellegrini F, Sacco M,; IGLOO (Impaired Glucose tolerance, and Long-term Outcomes Observational Study) Study Group. Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study. Clin J Am Soc Nephrol. 2007;2(5):984–991
   PubMed Web of Science ®Google Scholar
• . Kim YI, Kim CH, Choi CS,. Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population. Diabetes Res Clin Pract. 2001;52(2):145–152
   PubMed Web of Science ®Google Scholar
• . Suzuki H, Fukushima M, Usami M,. IGT with fasting hyperglycemia is more strongly associated with microalbuminuria than IGT without fasting hyperglycemia. Diabetes Res Clin Pract. 2004;64(3):213–219
   PubMed Web of Science ®Google Scholar
• . Tapp RJ, Shaw JE, Zimmet PZ,. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004;44(5):792–798
   PubMed Web of Science ®Google Scholar
• . Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin Pract. 2008;62(4):642–648
   PubMed Web of Science ®Google Scholar
• . Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454(7203):470–477
   PubMed Web of Science ®Google Scholar
• . Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144(6):2195–2200
   PubMed Web of Science ®Google Scholar
• . Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol. 2007;2:31–56
   PubMed Web of Science ®Google Scholar
• . Solinas G, Vilcu C, Neels JG,. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007;6(5):386–397
   PubMed Web of Science ®Google Scholar
• . Hevener AL, Olefsky JM, Reichart D,. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest. 2007;117(6):1658–1669
   PubMed Web of Science ®Google Scholar
• . Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118(9):2992–3002
   PubMed Web of Science ®Google Scholar
• . Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008;8(4):301–309
   PubMed Web of Science ®Google Scholar
• . Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–377
   PubMed Web of Science ®Google Scholar
• . Muoio DM, Newgard CB. Fatty acid oxidation and insulin action: when less is more. Diabetes. 2008;57(6):1455–1456
   PubMed Web of Science ®Google Scholar
• . Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med. 2005;2(9):e233
   PubMed Web of Science ®Google Scholar
• . Lyssenko V, Almgren P, Anevski D,; Botnia study group. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54(1):166–174
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493–500
   PubMed Web of Science ®Google Scholar
• . Abdul-Ghani MA, Matsuda M, Jani R,. The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab. 2008;295(2):E401–E406
   Web of Science ®Google Scholar
• . Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes. 2004;53(1):160–165
   PubMed Web of Science ®Google Scholar
• . Sattar N, McConnachie A, Ford I,. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes. 2007;56(4):984–991
   PubMed Web of Science ®Google Scholar
• . Bock G, Dalla MC, Campioni M,. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55(12):3536–3549
   PubMed Web of Science ®Google Scholar
• . Faerch K, Vaag A, Witte DR, Jorgensen T, Pedersen O, Borch-Johnsen K. Predictors of future fasting and 2-h post-OGTT plasma glucose levels in middle-aged men and women-the Inter99 study. Diabet Med. 2009;26(4):377–383
   PubMed Web of Science ®Google Scholar
• . Cubbon R, Kahn M, Kearney MT. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. Int J Clin Pract. 2008;62(2):287–299
   PubMed Web of Science ®Google Scholar
• . Fonseca VA. Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. Clin Cornerstone. 2007;8( suppl 7):S7–S18
   PubMedGoogle Scholar
• . Quiñones MJ, Hernandez-Pampaloni M, Schelbert H,. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med. 2004;140(9):700–708
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Cleary PA, Backlund JY,; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J,. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Miller ME, Byington RP,. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T,; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . D'Agostino RB Jr, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care. 2004;27(9):2234–2240
   PubMed Web of Science ®Google Scholar
• . Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation. 2006;113(14):1753–1759
   PubMed Web of Science ®Google Scholar
• . Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131–1137
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Danielson E, Fonseca FA; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Danielson E, Fonseca FA,; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . Auberger P, Falquerho L, Contreres JO,. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell. 1989;58(4):631–640
   PubMed Web of Science ®Google Scholar
• . Mathews ST, Singh GP, Ranalletta M,. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes. 2002;51(8):2450–2458
   PubMed Web of Science ®Google Scholar
• . Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes. 2005;54(8):2477–2481
   PubMed Web of Science ®Google Scholar
• . Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3(3):e1765
   Web of Science ®Google Scholar
• . Ix JH, Wassel CL, Kanaya AM,; Health ABD Study. Fetuin-A and incident diabetes mellitus in older persons. JAMA. 2008;300(2):182–188
   PubMed Web of Science ®Google Scholar
• . Weikert C, Stefan N, Schulze MB,. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118(24):2555–2562
   PubMed Web of Science ®Google Scholar
• . McGuire DK, Winterfield JR, Rytlewski JA, Ferrannini E. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res. 2008;5(1):59–66
   PubMed Web of Science ®Google Scholar
• . Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008;7:10
   PubMed Web of Science ®Google Scholar
• . Duvnjak L, Bulum T, Metelko Z. Hypertension and the metabolic syndrome. Diabetologia Croatica. 2008;37(4):83–89
   Google Scholar
• . Engeli S, Schling P, Gorzelniak K,. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35(6):807–825
   PubMed Web of Science ®Google Scholar
• . Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens. 1999;17(4):555–560
   PubMed Web of Science ®Google Scholar
• . Zappe DH, Sowers JR, Hsueh WA,. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2008;10(12):894–903
   PubMed Web of Science ®Google Scholar
• . Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286(5):H1597–H1602
   PubMed Web of Science ®Google Scholar
• . Leung KK, Leung PS. Effects of hyperglycemia on angiotensin II receptor type 1 expression and insulin secretion in an INS-1E pancreatic beta-cell line. JOP. 2008;9(3):290–299
   PubMedGoogle Scholar
• . Jonsson JR, Clouston AD, Ando Y,. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121(1):148–155
   PubMed Web of Science ®Google Scholar
• . Fonseca VA. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin Cornerstone. 2007;8(2):10–18
   PubMedGoogle Scholar
• . Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215–2221
   PubMed Web of Science ®Google Scholar
• . Hoerger TJ, Hicks KA, Sorensen SW,. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care. 2007;30(11):2874–2879
   PubMed Web of Science ®Google Scholar
• . Nichols GA, Arondekar B, Herman WH. Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care. 2008;14(12):791–798
   PubMed Web of Science ®Google Scholar
• . Triggle CR. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely Top Med Cardiovasc Dis. 2008;12:E3
   Google Scholar
• . Koopman RJ, Mainous AG 3rd, Everett CJ, Carter RE. Tool to assess likelihood of fasting glucose impairment (TAG-IT). Ann Fam Med. 2008;6(6):555–561
   PubMed Web of Science ®Google Scholar
• . Ratner R, Goldberg R, Haffner S,; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28(4):888–894
   PubMed Web of Science ®Google Scholar
• . Lauritzen T, Borch-Johnsen K, Sandbaek A. Is prevention of Type-2 diabetes feasible and efficient in primary care? A systematic PubMed review. Prim Care Diabetes. 2007;1(1):5–11
   PubMedGoogle Scholar
• . Anselmino M, Gohlke H, Mellbin L, Rydén L. Cardiovascular prevention in patients with diabetes and prediabetes. Herz. 2008;33(3):170–177
   PubMed Web of Science ®Google Scholar
• . Anselmino M, Mellbin L, Wallander M, Ryden L. Early detection and integrated management of dysglycemia in cardiovascular disease: a key factor for decreasing the likelihood of future events. Rev Cardiovasc Med. 2008;9(1):29–38
   PubMed Web of Science ®Google Scholar
• . Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack J; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186(9):461–465
   PubMed Web of Science ®Google Scholar
• . Rosenzweig JL, Ferrannini E, Grundy SM,. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(10):3671–3689
   PubMed Web of Science ®Google Scholar
• . Chahwala V, Arora R. Cardiovascular manifestations of insulin resistance. Am J Ther. 2009;16(5):e14–e28
   Google Scholar
• . Crandall JP, Knowler WC, Kahn SE,; Diabetes Prevention Program Research Group. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(7):382–393
   PubMedGoogle Scholar
• . Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism. 2009;58(7):946–953
   PubMed Web of Science ®Google Scholar
• . Green DJ, O'Driscoll G, Joyner MJ, Cable NT. Exercise and cardiovascular risk reduction: time to update the rationale for exercise? J Appl Physiol. 2008;105(2):766–768
   PubMed Web of Science ®Google Scholar
• . Wadden TA, West DS, Neiberg RH,; Look AHEAD Research Group. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713–722
   PubMed Web of Science ®Google Scholar
• . Jakicic JM, Jaramillo SA, Balasubramanyam A,; Look AHEAD Study Group. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes (Lond). 2009;33(3):305–316
   PubMed Web of Science ®Google Scholar
• . Pi-Sunyer FX. How effective are lifestyle changes in the prevention of type 2 diabetes mellitus? Nutr Rev. 2007;65(3):101–110
   PubMed Web of Science ®Google Scholar
• . Buchanan TA, Xiang AH, Peters RK,. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51(9):2796–2803
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–2077
   PubMed Web of Science ®Google Scholar
• . Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia. 2004;47(3):575–580
   PubMed Web of Science ®Google Scholar
• . Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161
   PubMed Web of Science ®Google Scholar
• . Xiang AH, Peters RK, Kjos SL,. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55(2):517–522
   PubMed Web of Science ®Google Scholar
• . Buchanan TA. (How) can we prevent type 2 diabetes? Diabetes. 2007;56(6):1502–1507
   PubMed Web of Science ®Google Scholar
• . Dagenais GR, Gerstein HC, Holman R,. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31(5):1007–1014
   PubMed Web of Science ®Google Scholar
• . Doctor's Guide. Pioglitazone prevents conversion to diabetes among insulin-resistant patients. Presented at: American Diabetes Association; San Francisco, CA; June 6–10, 2008. http://www.pslgroup.com/dg/2235da.htm. Accessed March 2, 2009
   Google Scholar
• . Sanyal AJ. A randomized controlled trial of pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS). Presented at: The Liver Meeting 2009; 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30–November 3, 2009; Boston, MA. Abstract LB2
   Google Scholar
• . Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10(12):1221–1238
   PubMed Web of Science ®Google Scholar
• . ACTOS (pioglitazone hydrochloride) tablets [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2009
   Google Scholar
• . Avandia (rosiglitazone maleate) tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008
   Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia. 2004;47(6):969–975
   PubMed Web of Science ®Google Scholar
• . Ando K, Fujita T. Anti-diabetic effect of blockade of the renin-angiotensin system. Diabetes Obes Metab. 2006;8(4):396–403
   PubMed Web of Science ®Google Scholar
• . Califf RM, Boolell M, Haffner SM,. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623–632
   PubMed Web of Science ®Google Scholar
• . ; NAVIGATOR Study GroupMcMurray JJ, Holman RR, Haffner SM,. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–1490
   PubMed Web of Science ®Google Scholar
• . Nathan DM. Navigating the choices for diabetes prevention. N Engl J Med. 2010;362(16):1533–1535
   PubMed Web of Science ®Google Scholar
• . Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30(6):487–496
   PubMed Web of Science ®Google Scholar
• . Zidek W, Schrader J, Lüders S,. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol. 2008;7:22
   PubMed Web of Science ®Google Scholar
• . US National Institutes of Health. A lifestyle and combination medication therapy diabetes prevention study. 2008. http://www.clinicaltrials.gov. Accessed February 23, 2009
   Google Scholar
• . US National Institutes of Health. The vascular effects of exenatide versus metformin in patients with pre-diabetes (NCT00546728). 2007. http://www.clinicaltrials.gov. Accessed February 23, 2009
   Google Scholar
• . Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8( suppl 2):S50–S62
   PubMed Web of Science ®Google Scholar
• . Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc. 2008;83(12):1373–1381
   PubMed Web of Science ®Google Scholar
• . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397–405
   PubMedGoogle Scholar
• . Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47(3):385–394
   PubMed Web of Science ®Google Scholar
• . Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24(3):447–453
   PubMed Web of Science ®Google Scholar
• . Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia. 1991;34(12):891–898
   PubMed Web of Science ®Google Scholar
• . Pan XR, Li GW, Hu YH,. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544
   PubMed Web of Science ®Google Scholar
• . Lindström J, Louheranta A, Mannelin M,. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26(12):3230–3236
   PubMed Web of Science ®Google Scholar
• . Carey VJ, Walters EE, Colditz GA,. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol. 1997;145(7):614–619
   PubMed Web of Science ®Google Scholar
• . Lindholm LH, Ibsen H, Dahlof B,. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004–1010
   PubMed Web of Science ®Google Scholar
• . Degl'Innocenti A, Elmfeldt D, Hansson L,. Cognitive function and health-related quality of life in elderly patients with hypertension—baseline data from the study on cognition and prognosis in the elderly (SCOPE). Blood Press. 2002;11(3):157–165
   PubMed Web of Science ®Google Scholar
• . Ogihara T, Nakao K, Fukui T,; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51(2):393–398
   PubMed Web of Science ®Google Scholar
• . Weber MA, Julius S, Kjeldsen SE,. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049–2051
   PubMed Web of Science ®Google Scholar
• . Kjeldsen SE, McInnes GT, Mancia G,. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Blood Press. 2008;17(3):170–177
   PubMed Web of Science ®Google Scholar
• . Fournier A, Pruna A, el Esper N,. Captopril prevention project—what shall we do about captopril and the risk of stroke? Nephrol Dial Transplant. 2000;15(1):2–5
   PubMed Web of Science ®Google Scholar
• . McQueen MJ, Lonn E, Gerstein HC, Bosch J, Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest. 2005;65( suppl 240):143–156
   Web of Science ®Google Scholar
• . Barzilay JI, Davis BR, Cutler JA,; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191–2201
   PubMed Web of Science ®Google Scholar